The global thalassemia market size is predicted to value at USD 3.53 billion by 2022, during the forecast period. The market is subject to observe substantial growth due to the rise in the occurrence of thalassemia diseases, and high-end demand for global cures. The factors driving the growth of the thalassemia industry are rising awareness about genetic disorders, and the adoption of modern techniques in the healthcare sector. The increase in incidences related to thalassemia are expected to grow in different regions of the globe due to factors such as growing populace immigration, mixed-race marriages, hereditary and environmental influences are the leading causes for the expansion of the market during the forecast period. Globally, the thalassemia market is predicted to grow at a CAGR of 10.8% in the forecast period, providing numerous opportunities for market players to invest in research and development in the thalassemia industry.
Most of the medicines that are consumed and prescribed to treat thalassemia are only capable of curing symptoms and their implication on the body is similar to anemia, the rise of iron in the blood, and lack of essential vitamins in the human body. The treatment for thalassemia is still considered non-viable despite, latest methodologies. These factors are hampering the market growth for thalassemia in recent years. Currently, the treatment associated with thalassemia is limited only to blood transfusion techniques and iron chelation therapy. Though, the advent of gene therapy has shown significant capabilities to cure thalassemia diseases in a short duration of time, re-energizing the growth of the thalassemia market in upcoming years.
Thalassemia is considered a hereditary blood disease caused due to variable production of hemoglobin in the human body. Patients suffering from thalassemia disorder cannot produce the required hemoglobin for proper functioning that leads to severe cases of anemia. Hemoglobin present in the red blood cells is responsible for oxygen supply to various parts of the body. Due to the lack of hemoglobin in blood cells, enough oxygen is not supplied to the body part for proper functioning. Thus, the body organs turn weak due to insufficient oxygen commonly, thalassemia disorder is classified into two types such as alpha thalassemia disorder and beta-thalassemia disorder. Critical importance is given to the treatment of beta-thalassemia disorder due to its severe effects. Beta-thalassemia is also termed Cooley’s anemia. The symptoms associated with the disease start appearing two to three years from the date of occurrence, these symptoms include pale skin, lack of hunger, irritability, and lack of growth. The common treatment associated with the disorder is routinely blood transfusions and iron chelation techniques. In thalassemia disorder, there is a substantial amount of iron production in the body due to the adverse effects of the disease.
Treatment or therapy of thalassemia solely relies on the level of severity in the patients. Majorly for alpha thalassemia disorders or mild forms of the disease condition, basic medication along with proper counseling is preferred. While in severe cases, a full-fledged treatment is required involving treatment blood transfusion, iron chelation therapy to maintain the concentration of iron in the blood. This can be achieved with the use of drugs, for example, deferoxamine and deferasirox.
The thalassemia industry is divided into regional market segments such as North America, Europe, Asia-Pacific, Latin America, and Africa. North America has shown major growth in recent years owing to the rise in the adoption of the latest technologies for the treatment of genetic disorders and the existence of well-established healthcare infrastructure. Europe region is predicted to hold a major market share in the thalassemia market with massive growth in the forecast period. Countries such as Italy, Germany, and France are leading the European market with an increase in the occurrence of thalassemia diseases and growing investment by leading industry players due to potential opportunities in the region.
The key players in the thalassemia industry are bluebird Incorporations, Acceleron Pharma Incorporations, Celgene Co., Incyte Co., Gamida Cell, Kiadis Pharma Co., La Jolla Pharmaceutical Company, and IONIS Co.
Thalassemia Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022)
• Iron Chelating Drugs
• Exjade/Jadenu (deferasirox)
Pipeline Outlook (Revenue, USD Million, 2016 - 2022)
• Gene Therapy
Regional Outlook (Revenue, USD Million, 2016 - 2022)
• the U.S.
• the U.K.
Research Support Specialist, USA
FREE sample contains market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...